Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $82.04 USD
Change Today -1.61 / -1.92%
Volume 6.6M
As of 8:04 PM 11/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lilly Corporate Center

Indianapolis, IN 46285

United States

Phone: 317-276-2000


a fixed-dose combination of empagliflozin and metformin hydrochloride. The company co-promotes Cymbalta in Japan with Shionogi & Co. Ltd. Erbitux is marketed in the U.S. and Canada by Bristol-Myers Squibb Company. The company has the option to co-promote Erbitux in the U.S. and Canada. Outside the U.S. and Canada, Erbitux is commercialized by Merck KGaA. Effient is co-promoted with the company by Daiichi Sankyo Co., Ltd. or affiliated companies in the U.S., major European markets, Brazil, Mexico, and certain other countries. The company retains sole marketing rights in Canada, Australia, Russia, and certain other countries. Daiichi Sankyo Co., Ltd. retains sole marketing rights in Japan and certain other countries. Animal Health Products The company’s Elanco animal health business unit employs field salespeople throughout the U.S. and has an extensive sales force outside the U.S. Elanco sells its products primarily to wholesale distributors. Elanco promotes its products primarily to producers and veterinarians for food animal products and to veterinarians for companion animal products. Elanco also advertises certain companion animal products directly to pet owners. Strategy The company’s Elanco animal health innovation strategy is focused on identifying and developing promising technologies and potential products from internal and external sources to meet unmet veterinary needs. Patents, Trademarks, and Other Intellectual Property Rights Intellectual Property Portfolio The relevant U.S. patent protection or data protection for the company’s patent-protected marketed products includes Alimta is protected by a compound patent (2016) plus pediatric exclusivity (2017), and a vitamin dosage regimen patent (2021) plus pediatric exclusivity (2022); Cialis is protected by compound and use patents (2017); Cyramza is protected by biologics data package protection (2026); Effient is protected by a compound patent (2017) and patents covering methods of using Effient with aspirin (2022); Forteo is protected by patents primarily covering its formulation and related processes (2018) and use patents (2019); Jardiance is protected by ­­­a compound patent (2025 not including possible patent extension); Strattera is protected by a patent covering its use in treating attention deficit-hyperactivity disorder (2016) plus pediatric exclusivity (2017); Trajenta and Jentadueto are protected by a compound patent (2023), and Boehringer Ingelheim has applied for a patent extension to 2025 under the patent restoration laws; and Trulicity is protected by a compound patent (2024 not including possible patent extension). Outside the U.S., primary patent protection or data protection comprises Alimta in major European countries (compound patent December 2015, vitamin dosage regimen patent 2021) and Japan (compound patent December 2015, patent covering use to treat cancer concomitantly with vitamins 2021); Cialis in major European countries (compound patent 2017); Cymbalta in Japan (data package protection 2018); Forteo in Japan (data package protection 2018; patent covering its formulation and related process 2019); and Zyprexa in Japan (compound patent December 2015). Patent Licenses The compound patent for Cialis is the subject of a license agreement with GlaxoSmithKline (Glaxo), which assigns to the company all rights in the compound. The compound patent for Alimta is the subject of a license agreement with Princeton University, granting the company an irrevocable exclusive worldwide license to the compound patents for the lives of the patents in the respective territories. Government Regulation Pursuant to the Federal Food, Drug, and Cosmetic Act, the U.S. Food and Drug Administration has jurisdiction over all of the company’s human pharmaceutical products and certain animal health products in the U.S. and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, advertising, dissemination of information, and post-marketing surveillance of those products. Outside the U.S., the company’s products and operations are subject


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:US $82.04 USD -1.61

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.92 USD -0.50
AbbVie Inc $58.15 USD -1.85
AstraZeneca PLC 4,503 GBp -10.00
Bristol-Myers Squibb Co $67.01 USD -0.84
Medtronic PLC $75.34 USD -1.12
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 37.8x
Price/Sales 4.5x
Price/Book 5.8x
Price/Cash Flow 39.3x
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at